21.8 C
New York
Monday, June 15, 2026

Tag: injection

KIA AMERICA ANNOUNCES 2026 SPORTAGE HEV PRICING

-  2026 Kia Sportage Hybrid has a starting MSRP of $30,2901-  Standard and X-Line models blend comfort and functionality-  Styling enhancements further elevate the...

Gran Tierra Energy Inc. Reports Second Quarter 2025 Results & Another Quarter of Record Production

CALGARY, Alberta, July 30, 2025 (GLOBE NEWSWIRE) -- Gran Tierra Energy Inc. (“Gran Tierra” or the “Company”) (NYSE American:GTE) (TSX:GTE) (LSE: GTE) announced the Company’s financial and operating results for the quarter ended June 30, 2025 (the “Quarter”) and provided an operational update. All dollar amounts are in United States (“U.S.”) dollars and all production volumes are on an average working interest before royalties (“WI”) basis unless otherwise indicated. Production is expressed in barrels (“bbl”) of oil equivalent (“boe”) per day (“boepd” or “boe/d”) and are based on WI sales before royalties. For per boe amounts based on net after royalty (“NAR”) production, see Gran Tierra’s Quarterly Report on Form 10-Q filed July 30, 2025.

KIA AMERICA ANNOUNCES 2026 SPORTAGE HEV PRICING

-  2026 Kia Sportage Hybrid has a starting MSRP of $30,2901-  Standard and X-Line models blend comfort and functionality-  Styling enhancements further elevate the...

Everads Announces Two Oral Presentations at ASRS 2025, Including Full Clinical Trial Results with Its Novel Suprachoroidal Injector

– Clinical study confirms safety, feasibility, and tolerability of the Everads Injector– – Preclinical data demonstrate the feasibility of in-office, minimally invasive suprachoroidal buckling using...

SUBARU ANNOUNCES PRICING ON 2026 IMPREZA

Sixth-generation Impreza with sporty 5-door hatchback design and standard Subaru Symmetrical All-Wheel DriveImpreza RS trim level now equipped with newly refined 2.5-liter, 180-hp SUBARU...

Tamarack Valley Energy Announces Q2 Results, Record Quarterly Production, Positive Guidance Update; Strategic Clearwater Tuck-in Acquisition and Executive Appointment

TSX: TVE CALGARY, AB, July 30, 2025 /CNW/ - Tamarack Valley Energy Ltd. ("Tamarack" or the "Company") (TSX: TVE) is pleased to announce its financial...

LipoVive Releases Ingredient Report Comparing Natural GLP-1 Support to Synthetic Drugs Like Mounjaro

A Plant-Based Formula With Science-Referenced Compounds Designed to Support Hormonal Weight Balance Without Prescription Medications
A Plant-Based Formula With Science-Referenced Compounds Designed to Support Hormonal Weight Balance Without Prescription Medications

ASYST Technologies Elevates Manufacturing Efficiency as a FANUC Authorized System Integrator

Turnkey automation solutions boost throughput, consistency, and free skilled workers for high-value tasks. KENOSHA, Wis., July 29, 2025 /PRNewswire/ -- ASYST Technologies, a leader in...

TOPAZ REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS DEMONSTRATING STRONG ROYALTY AND INFRASTRUCTURE GROWTH

CALGARY, AB, July 28, 2025 /CNW/ - Topaz Energy Corp. (TSX: TPZ) ("Topaz" or the "Company") is pleased to provide second quarter 2025 financial...

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union

NEW YORK and MAINZ, GERMANY, July 25, 2025Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the EMA’s Emergency Task Force (ETF) to update COVID-19 vaccines to target the LP.8.1 variant for the 2025-2026 season. The ETF stated that “targeting LP.8.1 will help maintain the effectiveness of the vaccines as SARS-CoV-2 continues to evolve.”2

HEADWATER EXPLORATION INC. ANNOUNCES SECOND QUARTER OPERATING AND FINANCIAL RESULTS AND DECLARES QUARTERLY DIVIDEND

CALGARY, AB, July 23, 2025 /CNW/ - Headwater Exploration Inc. (the "Company" or "Headwater") (TSX: HWX) is pleased to announce its operating and financial results for the...

Standard Motor Products Expands Turbocharger Program

Key Takeaways The Standard® Turbocharger program features complete, all-new, no-core Turbocharger Kits for gas and diesel vehiclesStandard® Turbocharger Kits include all of the related parts...

Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid...

Extended-release buprenorphine (BUP-XR) had lower rates of hospitalizations, emergency department (ED) visits, and outpatient physician office visits compared to those receiving daily oral buprenorphine or no medications for...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInjection